Recent Articles from GlobeNewswire

CERRITOS, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- GEN Restaurant Group, Inc. (“GEN” or the “Company”) (Nasdaq: GENK), operator of GEN Korean BBQ, one of the largest full-service Korean BBQ restaurant chain in the United States, today announced that its ready-to-cook marinated meat products have been accepted for retail placement at Smart & Final Stores LLC (“Smart & Final”), a leading warehouse-style grocery chain operated by Chedraui USA, Inc.

GEORGE TOWN, Cayman Islands, June 15, 2026 (GLOBE NEWSWIRE) -- Toobit, the award-winning global cryptocurrency exchange, today announces an upgrade to its security ecosystem. By consolidating defensive protocols, independent audit findings, and verification tools into one comprehensive hub, the exchange provides traders with a transparent view of the infrastructure protecting their assets.At the core of this defense is Bee-Safe technology, Toobit's proprietary multi-layered system that integrates hardware encryption, AI-driven risk controls, and continuous system auditing. The updated security hub serves as a central repository where traders can access detailed information on cold storage practices, data protection standards, and the exchange's security architecture.Beyond these technical disclosures, the resource includes security-first educational materials and practical guides on account protection, removing the complexity often associated with exchange-level security.

Mesquite, NV, June 15, 2026 (GLOBE NEWSWIRE) -- Mesquite, NV – June 15, 2026 – Dogecoin Cash, Inc. (OTC: DOGP) today announced the filing of a U.S. utility patent application with the United States Patent and Trademark Office (USPTO) covering core technologies underlying the Company’s DOGP blockchain development ecosystem.

VANCOUVER, British Columbia, June 15, 2026 (GLOBE NEWSWIRE) -- Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) announces that the Company has received the environmental decree from Senegal’s Ministry of Environment and Ecological Transition approving the Environmental and Social Impact Assessment for the Diamba Sud Gold Mine. This authorization certifies that the project complies with all applicable environmental regulations and has been socially accepted by the project’s stakeholders. It marks a decisive step towards obtaining the mining permit following the submission of its application to the Ministry of Energy, Petroleum, and Mines on February 4, 2026.

Vallourec Geothermal Deep Dive

BUFFALO, N.Y. , June 15, 2026 (GLOBE NEWSWIRE) -- Austin Air Systems announced the launch of an expanded Wildfire Toolkit and the introduction of a new seven-part educational video series focused on wildfire smoke and its potential effects on indoor environments and public health. The initiative is intended to provide individuals, families, and professionals with access to educational resources as wildfire activity continues to affect communities across the United States.

KIGALI, Rwanda and SAN FRANCISCO, June 15, 2026 (GLOBE NEWSWIRE) -- Bio Usawa, a biotechnology company dedicated to expanding access to high-quality biologic medicines across Africa, today announced the appointment of Dr. Aida Habtezion to its Board of Directors. Her appointment marks a significant milestone as the company accelerates its efforts to build sustainable biotechnology manufacturing capacity on the continent and improve access to life-changing therapies for patients across Africa.

First biodistribution study of the Company’s complete cancer targeting nanoparticle avoided many healthy organs

BONN, Germany, June 15, 2026 (GLOBE NEWSWIRE) -- Mavenir, the software company building Cloud-Native, AI-by-design mobile networks, today announced to be the first tier-1 telecommunications infrastructure software provider to receive the BSI NESAS certification for a 5G Packet Core network function. The certificate confirms that the Mavenir Network Repository Function (NRF) fulfils the security standard requirements for use as a critical component in public telecommunications networks in Germany.

Overall retail spending rose 1.3% year over year, while unit demand declined 1.5%, signaling a more selective and value-conscious shopper.

PRESS RELEASE

ING appoints Hilde Garssen to the Management Board Banking

SHELL PLC FIRST QUARTER 2026 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS

RUEIL-MALMAISON, France and TAIPEI, Taiwan, June 15, 2026 (GLOBE NEWSWIRE) -- Schneider Electric, a global energy technology leader, today announced a strategic collaboration with Hon Hai Technology Group (Foxconn), the world’s largest electronics manufacturer, to help define and scale the next generation of AI data centers.

BEIJING, June 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 40 clinical studies of the Company's novel BTK inhibitor orelabrutinib were presented at the European Hematology Association (EHA) 2026 Congress. Clinical data on the efficacy and safety of orelabrutinib in treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients from the United States and Europe was released for the first time.

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

Announced at FIRSTCON26, Modat brings Passive DNS to Magnify: one pivot from any signal to every related piece of attacker infrastructure

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab’s potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.

Join BTC and top assets through AI-driven automated strategies with daily settlement—no manual trading needed.

Urge all eligible individuals to donate blood

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels. Building on Celldex’s leadership in mast cell science, the data also demonstrated that neutralizing soluble stem cell factor (SCF) enables the potential for meaningful mast cell inhibition and depletion without impacting other KIT-dependent functions. CDX-622 is currently being studied in a Phase 1b proof of mechanism study in mild to moderate asthma to assess the impact of dual neutralization of SCF and TSLP.

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

ANN ARBOR, Mich., June 13, 2026 (GLOBE NEWSWIRE) --

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Zscaler To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BitGo To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Badger Meter To Contact Him Directly To Discuss Their Options

Join XRP and top assets through AI-driven automated strategies with daily settlement—no manual trading needed.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AeroVironment To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Roblox To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Calix To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Globant To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regencell To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lucid Group To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Veritone To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Phreesia To Contact Him Directly To Discuss Their Options

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

Created by the Intelligent Racing Foundation and jointly operated with Beijing Beiao Group Co., Ltd. (“Beiao Group”), the event will bring the world’s top teams to the National Speed Skating Oval (Ice Ribbon) to spark the defining breakthrough moment of physical intelligence

MIAMI, June 12, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced that trading in shares of the Defiance Daily 2X Space ETF (Cboe BZX: SPCL) was temporarily halted by Cboe BZX Exchange, Inc. (the “Exchange”).

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options.

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53,000 people in the U.S. alone, and there are currently no approved treatment options for the disease.

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Futu Holdings Limited (“Futu” or the “Company”) (NASDAQ:FUTU) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

British Novelist Honored at Hôtel Belles Rives for ‘Départ(s)’ at the Prize’s 15th Edition

Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA).

Agencies Partner to Remove Foreign Imposters from List of Approved Federal Product Offerings

LONDON/HOUSTON/SINGAPORE, June 12, 2026 (GLOBE NEWSWIRE) -- Cushing crude storage levels have plummeted in recent months. Inventories fell 11.3 million barrels (mmbbls) to less than 25 mmbbls between early April and early June, according to Wood Mackenzie. The firm's monitoring spans fixed-roof tanks, caverns, and floating-roof tanks, producing more complete and reliable datasets than satellite-sourced alternatives. While satellite data can estimate volumes in floating-roof tanks, it cannot measure levels in fixed-roof tanks or underground storage caverns. This comprehensive coverage gives Wood Mackenzie unique visibility into US and global crude storage dynamics.

Vancouver, BC, June 12, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) has granted an aggregate 47,013 stock options, exercisable at $0.71 per share and valid for a term of three years, and an aggregate 514,801 restricted share units, valid for a term between one to three years, to consultants and employees of the Company and its subsidiaries.  The stock options and restricted share units are issued pursuant to the Company’s share compensation plans and are subject to a statutory hold period of four months and one day from issuance, in addition to vesting provisions.Additionally, and further to the Company’s news release dated July 18, 2025, the Company has extended the marketing services provided by 45 Degrees, Inc. (“45 Degrees”) and Investment Publishing LLC (“Investment Publishing”) to provide digital marketing and investor awareness services until September 30, 2026. No additional compensation shall be payable to 45 Degrees or Investment Publishing for the additional services provided.

MONTREAL, June 12, 2026 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; “BRW” or the “Company”) is pleased to announce the results of its annual general meeting (“AGM”) of shareholders held on June 11, 2026. Shareholders holding a total of 88,315,188 common shares of the Corporation attended the AGM in person or were represented by proxy, representing approximately 31.27 % of the 282,392,131 common shares issued and outstanding.

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) -- Lotus Technology Inc. (Nasdaq: LOT) (“Lotus Tech” or the “Company”), a leading global intelligent and luxury mobility provider, today provided an update on recent developments and announced the temporary suspension of the publication of earnings releases for the first quarter and third quarter of fiscal year 2026.

SOUTHAMPTON, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation (OTCID: ETCC) (“ETC” or the “Company”) today reported its financial results for the thirteen week period ended February 27, 2026 (the “2026 fiscal fourth quarter”) and the fifty-two week period ended February 27, 2026 (“fiscal 2026”).

Trump action reopens nearly half a million square miles to commercial fishing, boosting small businesses and coastal economies

— Capacity exits, rising demand, and Strait of Hormuz disruptions converge to threaten drayage and intermodal operations for 2026 peak —

KENOSHA, Wis. and ULM, Germany, June 12, 2026 (GLOBE NEWSWIRE) -- Unified Information Devices, Inc. (UID), a leader in RFID- enabled monitoring for medical research, today announced that it has completed the acquisition of AEG Identifikationssysteme GmbH (AEG ID), including its headquarters in Ulm, Germany, and manufacturing operations in the Czech Republic.

Shakopee, Minn., June 12, 2026 (GLOBE NEWSWIRE) -- Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (NASDAQ: CPHC), today announced that the Company’s Board of Directors, pursuant to its dividend policy, approved a quarterly cash dividend of $0.07 per share that will be paid on July 14, 2026 to stockholders of record on June 30, 2026. At this quarterly rate, the annual dividend is equivalent to $0.28 per common share.

EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced that its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s (i) 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) (the “Series A Preferred Stock”) (984,000 shares outstanding, CUSIP No. 98419J305) and (ii) depositary shares representing its 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) (represented by 1,760,500 Depositary Shares) (the “Series B Preferred Stock”, and together with the Series A Preferred Stock, the “Preferred Stock”) (CUSIP No. 98419J404). In addition, on July 14, 2026 (the “Redemption Date”), it will redeem all outstanding shares of Preferred Stock, in each case pursuant to Section 5(b) of the applicable Certificate of Designation.

EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on June 9, 2026, the compensation committee of the Company’s board of directors granted seven new non-executive employees 66,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

Emphasis remains on commitment to transparency, customer protection and community engagement

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) --

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss interim six-month results from the Company’s Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) --

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) --

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Kemper (KMPR) To Contact Him Directly To Discuss Their Options

CHICAGO, June 12, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has received new contract manufacturing orders from Nassington and Verisfield for a combined 253,657 units across a range of medicines and other pharmaceutical products.